Eric Trachtenberg

Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA.

KOS Pharmaceuticals, Inc. operates as pharmaceutical company that developed and commercialized proprietary prescription products for the treatment of chronic cardiovascular, metabolic and respiratory diseases. The company is founded by Daniel M. Bell and Michael Jaharis in 1988 and is headquartered in Cranbury, NJ.

POZEN, Inc. manufactures and markets pharmaceutical products. Its Pipeline products are PA Product Portfolio, which is focused on integrated aspirin therapies that enable the full power of aspirin by reducing its potential gastrointestinal damage. The firm PA Product Portfolio consists of PA8140 and PA32540. The company was founded by John R. Plachetka in 1996 and is headquartered in Raleigh, NC.

Auxilium Pharmaceuticals LLC develops and markets pharmaceutical products. It specializes in men's healthcare area and has product portfolio and pipeline in orthopedics, dermatology and other therapeutic areas. The firm products include edex, Osbon, ErecAid, STENDRA, TESTOPEL, XIAFLEX and Testim. The company was founded by Gerri A. Henwood and Jane Holmes Hollingsworth in 1999 and is headquartered in Chesterbrook, PA.

Blank Rome LLP provides legal services. The firm's services include commercial litigation, labor and employment benefits, bankruptcy, energy, financial services, health care, shareholder activism, tax and many more. The company was founded in 1946 and is headquartered in Philadelphia, PA.

Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada.

Aralez Pharmaceuticals Inc. engages in the development, acquisition, and commercialization of cardiovascular, pain, and other product therapies. It operates through the following geographical segments: United States and Canada. The company is founded on December 2, 2015, and is headquartered in Mississauga, Canada.